Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3696]

$EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in relapsed / refractory multiple myleoma$

EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related...

$EHA 2019: Overcoming the "Don’t Eat Me" signal of refractory lymphomas$

EHA 2019: Overcoming the "Don’t Eat Me" signal of refractory lymphomas

EHA 2019: Phase 3 randomised study of daratumumab plus D-VTd vs VTd in transplant-eligible newly diagnosed multiple myeloma

EHA 2019: Phase 3 randomised study of daratumumab plus D-VTd vs VTd in transplant-eligible newly diagnosed...

EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities

EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously...

Radiation plus chemotherapy doesn't improve endometrial cancer recurrence-free survival

Radiation plus chemotherapy doesn't improve endometrial cancer recurrence-free survival

Three-drug combination helps curb the growth of deadly type of skin cancer

Three-drug combination helps curb the growth of deadly type of skin cancer

ASCO 2019: Novel targeted-antibody treatment produced responses in nearly half of patients with advanced urothelial cancer

ASCO 2019: Novel targeted-antibody treatment produced responses in nearly half of patients with advanced...

ASCO 2019: Maintenance therapy with PARP inhibitor olaparib delays progression of BRCA-related pancreatic cancer

ASCO 2019: Maintenance therapy with PARP inhibitor olaparib delays progression of BRCA-related pancreatic cancer

ASCO 2019: Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone-sensitive prostate cancer

ASCO 2019: Adding enzalutamide to standard first-line treatment improves survival for men with metastatic hormone...

ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

More from ecancer